Semaglutide may reduce fracture risk

Clinical takeaway: For type 2 diabetes patients where fracture risk is a concern, the choice of weight-loss drug may matter, with semaglutide showing a lower fracture rate than some alternatives.

Rapid weight loss tends to accelerate bone loss, which raises fracture risk. This concern has increased recently since GLP-1s produce larger drops in weight than older drugs. Type 2 diabetes adds to the danger, since the disease weakens bone on its own. New data suggest the choice of weight loss drug may shape how much fracture risk follows.

Semaglutide-treated patients had 15% fewer fractures than the comparator group (794 versus 1,045 fractures) over a mean follow-up of roughly 3.6 years. That came alongside greater weight loss, not less. Among patients with BMI data, semaglutide drove a slightly larger one-year decrease (1.9 versus 1.2 BMI points).

The retrospective cohort study drew on the Atropos Health Eos electronic health record dataset, covering adults with type 2 diabetes and no prior fractures or osteoporosis treatment. It compared semaglutide against dulaglutide, phentermine-topiramate, or bupropion-naltrexone, matching about 17,500 patients per group on a wide range of baseline characteristics. BMI figures came from a smaller subset with available data.

The findings, presented at the Endocrine Society's annual meeting (ENDO 2026), have not yet undergone peer review. The result complicates the usual expectation that more weight loss translates directly into more bone loss. It raises the possibility that semaglutide acts on bone independent of weight. But the comparison was against other active drugs, not placebo, so the finding speaks to relative risk among weight-loss options, not whether semaglutide is protective of bone. Why one GLP-1 outperformed another on fractures remains an open question.

"Bone fractures are painful, expensive and can seriously affect quality of life," said Jairo Noreña, MD, a former endocrinology fellow at Stanford University Medical Center. The team hopes the findings encourage bone-health monitoring in weight-loss programs.

Source: Kim SH, et al. Endocrine Society Annual Meeting, Abstract ORF34-04. June 14, 2026. Association between Semaglutide and Risk of Bone Fractures in Type 2 Diabetes